The Boston University Alzheimer's Disease Center (BU ADC) facilitates a wide range of research on clinical-pathological correlations in normal aging, mild cognitive impairment (MCI) and dementia;genetic and environmental risk and protective factors for AD;pathogenesis and animal models of neurodegeneration;and interventions to prevent and treat AD. The BU ADC provides access to registry participants, postmortem brain tissue, DNA and transgenic mice to qualified investigators and funds innovative pilot projects. The BU ADC is composed of six cores. The Administrative Core oversees the BU ADC, ensures optimal resource utilization and coordinates and integrates BU ADC activities. The Clinical Core recruits and comprehensively evaluates, a Patient/Control Registry with more than 600 participants annually. The Data Management and Statistics Core provides infrastructure to optimize the information flow and maintains databases to define resources available to investigators. The Neuropathology Core establishes accurate, comprehensive neuropathological diagnoses, facilitates clinicopathological studies, and provides tissue to investigators. The Education and Information Transfer Core conducts a wide range of education, outreach, and recruitment activities to support the Center. The Murine Breeding and Molecular Genetics Core provides transgenic mice and genotyping services to investigators. The BU ADC supports national AD research by collecting and transmitting a uniform data set (UDS) to the National Alzheimer's Coordinating Center (NACC). The BU ADC is a platform for training medical and graduate students, fellows and junior faculty in AD research. Consistent with the RFA, the BU ADC has shifted focus from late stage dementia to concentrate on research on normal aging and the transition from normal aging to MCI and to the earliest stages of dementia. The BU ADC has made a special effort to address the needs of, and research with, ethnically diverse populations. Twenty percent of Registry participants are African American. The BU ADC collaborates with major NIH-funded studies on vascular risk factors and AD including the Framingham Heart Study, MIRAGE, ADNI, ADCS, REVEAL and the Honolulu-Asian Aging study and leads a NACC-funded Vascular Neuropathology Consortium. In the next funding cycle the BU ADC will continue to provide essential resources to increase research productivity, help generate new ideas, and facilitate collaborative AD-related research.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG013846-15
Application #
7892346
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (M1))
Program Officer
Silverberg, Nina B
Project Start
1997-07-01
Project End
2011-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
15
Fiscal Year
2010
Total Cost
$1,220,077
Indirect Cost
Name
Boston University
Department
Neurology
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Li, Dan; Wang, Lei; Maziuk, Brandon F et al. (2018) Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau. J Biol Chem 293:12081-12094
Tagge, Chad A; Fisher, Andrew M; Minaeva, Olga V et al. (2018) Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model. Brain 141:422-458
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Chung, Jaeyoon; Wang, Xulong; Maruyama, Toru et al. (2018) Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages. Alzheimers Dement 14:623-633
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416

Showing the most recent 10 out of 791 publications